That's right, Joanne. The IP was owned by CanSino. It was not NRC IP that was involved in the vaccine. CanSino did have access to the HEK-293 cell line, which is very advanced and used by many vaccine companies in the development of the product. However, all of the IP related to this particular vaccine was actually CanSino's, not the NRC's, and no money was paid to CanSino.
On February 26th, 2021. See this statement in context.